Price talks resume on CF drug
Talks on a price agreement for the new cystic fibrosis drug Orkambi resumed between the HSE and the pharmaceutical company Vertex in Dublin yesterday.
The costly drug has already been turned down as too expensive by the HSE, which wants the company to dramatically reduce the price before making it available.
More than 500 people with cystic fibrosis are desperate to try the drug. HSE chief Tony O'Brien cautioned against over-optimism while Health Minister Simon Harris said they would not be "bullied or intimidated".
He hopes to get the support of England, Scotland, Canada and Australia in securing a price for the drug.
However, two other countries are understood to have already joined forces in a similar bid.